Uploaded October 2026 | Updated November 2026, 3 hours ago
In this session from the 2026 Rare Neuroimmune Disorders Symposium (RNDS), Benjamin Greenberg, MD, MHS, of the University of Texas Southwestern, Carlos A. Pardo, MD, of Johns Hopkins University, and Shuvro Roy, MD, of the University of Washington discussed how diagnosis of rare neuroimmune disorders has changed over 25 years [00:01:25]. Dr. Pardo described how registries and stored blood and spinal fluid samples led to the discovery of the aquaporin-4 and MOG antibodies, and why listening to the person in front of you still matters [00:02:49]. Dr. Greenberg explained how clinicians learn to recognize new conditions, using acute flaccid myelitis as an example, and Dr. Roy described how understanding of MOG antibody disease (MOGAD) has evolved, including the 2023 diagnostic criteria and the gray areas that remain [00:08:39]. The panel explained why antibody tests differ between labs, why timing and levels matter, and why a test result is not a diagnosis by itself [00:15:50]. They also cautioned about direct-to-consumer testing panels [00:25:57].
Benjamin Greenberg, MD, MHS, directs the Transverse Myelitis and Neuromyelitis Optica Program at the University of Texas Southwestern Medical Center and is recognized internationally as an expert in rare autoimmune disorders of the central nervous system. His research focuses on better ways to diagnose and treat these disorders, including biomarkers that may help distinguish between neurologic conditions.
Carlos A. Pardo, MD, is a Professor of Neurology and Pathology in the Division of Neuroimmunology and Neuroinfectious Disorders at Johns Hopkins University School of Medicine and Director of the Johns Hopkins Myelitis and Myelopathy Center in Baltimore, Maryland. He is the principal investigator of the Neuroimmunopathology Laboratory and a clinical neurologist at the Multiple Sclerosis and Transverse Myelitis Centers at Johns Hopkins Hospital. His clinical specialization is neuroimmunological and infectious disorders of the nervous system, with particular focus on multiple sclerosis, transverse myelitis, neurosarcoidosis, and neurological complications of autoimmune disorders.
Shuvro Roy, MD, is an Assistant Professor of Neurology at the University of Washington, specializing in neuroimmunology, with a focus on multiple sclerosis and related neuroimmunologic disorders. He is Co-Director of the UW SRNA Center of Excellence for Rare Neuroimmune Disorders. Dr. Roy is engaged in projects aimed at improving access to care, addressing healthcare disparities, and enhancing patient safety for people living with MS and related conditions.
00:00 Welcome and Introductions
01:25 How Diagnosis Has Changed
02:49 Registries, Samples and Listening
08:39 Recognizing New Conditions
11:26 Learning About MOGAD
15:50 Why Antibody Tests Differ
21:14 A Test Result Is Not a Diagnosis
25:57 Direct-to-Consumer Testing
29:45 Putting the Pieces Together
In this session from the 2026 Rare Neuroimmune Disorders Symposium (RNDS), Benjamin Greenberg, MD, MHS, of the University of Texas Southwestern, Carlos A. Pardo, MD, of Johns Hopkins University, and Shuvro Roy, MD, of the University of Washington discussed how diagnosis of rare neuroimmune disorders has changed over 25 years [00:01:25]. Dr. Pardo described how registries and stored blood and spinal fluid samples led to the discovery of the aquaporin-4 and MOG antibodies, and why listening to the person in front of you still matters [00:02:49]. Dr. Greenberg explained how clinicians learn to recognize new conditions, using acute flaccid myelitis as an example, and Dr. Roy described how understanding of MOG antibody disease (MOGAD) has evolved, including the 2023 diagnostic criteria and the gray areas that remain [00:08:39]. The panel explained why antibody tests differ between labs, why timing and levels matter, and why a test result is not a diagnosis by itself [00:15:50]. They also cautioned about direct-to-consumer testing panels [00:25:57].
Benjamin Greenberg, MD, MHS, directs the Transverse Myelitis and Neuromyelitis Optica Program at the University of Texas Southwestern Medical Center and is recognized internationally as an expert in rare autoimmune disorders of the central nervous system. His research focuses on better ways to diagnose and treat these disorders, including biomarkers that may help distinguish between neurologic conditions.
Carlos A. Pardo, MD, is a Professor of Neurology and Pathology in the Division of Neuroimmunology and Neuroinfectious Disorders at Johns Hopkins University School of Medicine and Director of the Johns Hopkins Myelitis and Myelopathy Center in Baltimore, Maryland. He is the principal investigator of the Neuroimmunopathology Laboratory and a clinical neurologist at the Multiple Sclerosis and Transverse Myelitis Centers at Johns Hopkins Hospital. His clinical specialization is neuroimmunological and infectious disorders of the nervous system, with particular focus on multiple sclerosis, transverse myelitis, neurosarcoidosis, and neurological complications of autoimmune disorders.
Shuvro Roy, MD, is an Assistant Professor of Neurology at the University of Washington, specializing in neuroimmunology, with a focus on multiple sclerosis and related neuroimmunologic disorders. He is Co-Director of the UW SRNA Center of Excellence for Rare Neuroimmune Disorders. Dr. Roy is engaged in projects aimed at improving access to care, addressing healthcare disparities, and enhancing patient safety for people living with MS and related conditions.
00:00 Welcome and Introductions
01:25 How Diagnosis Has Changed
02:49 Registries, Samples and Listening
08:39 Recognizing New Conditions
11:26 Learning About MOGAD
15:50 Why Antibody Tests Differ
21:14 A Test Result Is Not a Diagnosis
25:57 Direct-to-Consumer Testing
29:45 Putting the Pieces Together
![2024 RNDS | What’s my Diagnosis? Community Members Share their Diagnostic Journey
At the 2024 RNDS, Dr. GG deFiebre of the Siegel Rare Neuroimmune Association (SRNA) spoke with community members, Angela Jackson, Andrew Jopson, Ashley Harrington, Lyd Lacey and Andreas Melitsanopoulos about their diagnostic journey. The participants shared their diagnostic journeys and the onset of their symptoms [00:00:30]. The conclusion revealed the specific diagnoses of each participant and emphasized the similarities and differences in their experiences [00:35:55].
00:00 Introduction and Panel Overview
00:37 Panelist Introductions
01:29 Initial Symptom Onset
07:39 Detailed Symptom Experiences
21:49 Diagnostic Tests and Challenges
27:22 Initial Treatments and Responses
30:24 Personal Reflections and Support
35:55 Revealing the Diagnoses
37:36 Conclusion and Organizational Impact 2024 RNDS | What’s my Diagnosis? Community Members Share their Diagnostic Journey](https://i.ytimg.com/vi/U4awgJE6lxo/mqdefault.jpg)
![Ask the Expert 1403. Open Q&A on MOG Antibody Disease (MOGAD)
In this SRNA Ask the Expert episode moderated by Krissy Dilger, Dr. John Chen of the Mayo Clinic answered audience questions about MOG antibody disease (MOGAD). He discussed diagnosis and the importance of titers and live cell-based assays given possible false positives [00:02:42]. Dr. Chen reviewed acute management with early high-dose steroids, prolonged tapers, and escalation to plasma exchange for severe or steroid-refractory attacks, as well as evolving long-term options including IVIG/subcutaneous IG and IL-6 blockade [00:04:14]. Audience questions covered relapse prediction, vision recovery timelines, fatigue, pregnancy, heredity, symptom interpretation, and whether to stop immunotherapy when antibodies become undetectable [00:12:13]. Finally, Dr. Chen described current and upcoming research, including a trial that is currently enrolling participants, and future prospects for optic nerve regeneration while cautioning against unproven stem cell clinics [00:41:37].
John J. Chen, MD, PhD attended the University of Virginia for his undergraduate and combined MD/PhD degrees and completed his Ophthalmology residency and Neuro-Ophthalmology fellowship training at the University of Iowa. He then took a position at the Mayo Clinic in 2014 where he specializes in Neuro-Ophthalmology. Currently, he serves as a Consultant and Professor of Ophthalmology and Neurology, and Neuro-Ophthalmology Fellowship Director at the Mayo Clinic.
Among Dr. Chen’s awards and honors are the AAO Senior Achievement Award, Top Doctors in Minnesota, the Heed Fellowship, Real World Ophthalmology Inspiring Academic Leader Award, Ophthalmology Teacher of the Year Award four times leading to induction to the Educators Hall of Fame, and the Mayo Clinic Distinguished Educator Award – awarded to the top educator at Mayo Clinic in Rochester. He is an Associate Editor for Ophthalmology and the Journal of Neuro-Ophthalmology, has authored more than 250 peer-reviewed publications, and focuses his research on ophthalmic imaging, idiopathic intracranial hypertension, and optic neuritis, particularly NMOSD and MOG antibody–associated disease.
00:00 Welcome and Introductions
01:08 What Is MOGAD?
02:42 Causes and Triggers
03:23 How MOGAD Is Diagnosed
04:14 Acute Attack Treatments
06:35 Steroid Side Effects
08:13 Testing During Treatment
09:09 Long Term Therapies
12:13 Interpreting MOG Positivity
16:51 Eye Symptoms and Vision Fluctuations
20:12 Antibody Titers and Severity
21:19 Relapse Risk After First Attack
23:09 Seizures and Encephalitis
24:17 Vision Recovery After Optic Neuritis
25:13 Acute Treatment Window
25:57 Hereditary Risk Questions
26:35 Stopping Azathioprine Safely
29:56 Managing Post Attack Pain
30:16 Steroids IVIG and Plasma Exchange
32:08 Infections as Triggers
33:01 Retesting MOG Antibodies
35:01 Fatigue and Workup
36:23 Prognosis and Life Expectancy
37:45 Tinnitus and Brain Pressure
39:05 Pediatric and Pregnancy Concerns
41:37 Trials and Future Regeneration
46:05 Research Resources and Wrap Up Ask the Expert 1403. Open Q&A on MOG Antibody Disease (MOGAD)](https://i.ytimg.com/vi/Un3Sx3YzPi4/mqdefault.jpg)


![Community Meets Clinic 305. Dr. Elena Grebenciucova
The Community Meets Clinic podcast series introduces clinicians and healthcare personnel specializing in rare neuroimmune disorders. In this episode, Krissy Dilger of SRNA spoke with Dr. Elena Grebenciucova, an assistant professor of neurology and neurological infections at Northwestern University in Chicago, Illinois, leading its Transverse Myelitis Center, a designated Center of Excellence in Rare Neuroimmune Disorders. She described Northwestern’s multidisciplinary clinic for transverse myelitis, NMOSD, MOGAD, neurosarcoidosis, and related autoimmune conditions, including collaboration with Shirley Ryan AbilityLab and specialists such as pain management, neuro-urology, rehabilitation, and neurosurgery, with an emphasis on faster access to care [04:08]. Dr. Grebenciucova outlined research and clinical trial efforts, including studies on transverse myelitis natural history, optic neuritis therapies, plasma exchange timing, and CAR T-cell strategies [08:36]. View the medical profile of Dr. Grebenciucova:
https://www.nm.org/doctors/1467708305/elena-grebenciucova-md
Elena Grebenciucova, MD completed neurology residency at the University of Chicago in Chicago, Illinois. Dr. Grebenciucova has been interested in autoimmune disorders of the central nervous system, including rare neuroimmune disorders, since medical school. After residency, she completed a neuroimmunology Fellowship under the mentorship of Dr. Brenda Banwell and Joseph Berger at the Perelman School of Medicine of The University of Pennsylvania. Currently she is an assistant professor of Neurology (MS/Neuroimmunology) and neurological infections at Northwestern University in Chicago, Illinois, and she runs the Transverse Myelitis Center there. Dr. Grebenciucova sees patients with rare autoimmune conditions including NMOSD, MOGAD, transverse myelitis, and autoimmune encephalitis.
00:00 Series Introduction
00:52 Meet Dr. Elena Grebenciucova
01:38 Her Path to Neuroimmunology
04:08 Northwestern TM Clinic Overview
08:36 Research and Clinical Trials
11:16 How to Access the Clinic
12:46 Multidisciplinary Care Team
15:32 Self Care and Lifestyle
18:55 Why Choose Northwestern
21:45 Hope for the Future
23:17 Closing Community Meets Clinic 305. Dr. Elena Grebenciucova](https://i.ytimg.com/vi/VcTv_MOWst8/mqdefault.jpg)
![Community Meets Clinic 307. Dr. Melissa Wright
In this episode Krissy Dilger met with Dr. Melissa Wright of the University of Utah and Intermountain Primary Children’s Hospital, a designated Center of Excellence in Rare Neuroimmune Disorders. Dr. Melissa Wright shared how her training in neuroscience and personal experiences as a parent led her into pediatric neurology and rare neuroimmune disorders [00:01:32]. She discussed her research focus on improving pediatric-to-adult healthcare transitions and advancing clinical trial readiness through implementation science to bring meaningful evidence-based care to patients [00:06:17]. Dr. Wright described how patients connect with her multidisciplinary neuroimmunology clinic, the team-based supports available (including nursing coordination, social work, and subspecialists), and her hope for more prospective studies and randomized controlled trials to guide future treatment [00:12:48]. View the medical profile of Dr. Melissa Wright:
https://healthcare.utah.edu/find-a-doctor/melissa-wright
Melissa A. Wright, MD is a pediatric autoimmune neurologist at the University of Utah and serves as Director of the Pediatric Autoimmune Neurology and Neuroimmunology Program at Primary Children’s Hospital. She completed medical school and child neurology residency at the University of Utah, followed by fellowship training in Autoimmune Neurology.
Her clinical and research efforts focus on improving the diagnosis and care of children with neuroinflammatory conditions. She is committed to advancing care that reflects the needs of patients, families, and caregivers, with particular emphasis on improving healthcare transitions for adolescents and young adults living with rare autoimmune neurologic diseases.
00:00 Meet Dr. Wright
01:32 Dr. Wright’s Journey
03:43 Why Neuroimmune Disorders
06:17 Research Focus Areas
10:26 Clinic Access and Referrals
12:48 Multidisciplinary Care Team
16:17 Self Care Outside Medicine
18:10 What Families Should Know
22:27 Hope for the Future
24:26 Closing Community Meets Clinic 307. Dr. Melissa Wright](https://i.ytimg.com/vi/W5Bb0GCLusg/mqdefault.jpg)


![2026 RNDS | How to Get Involved in Research
In this session from the 2026 Rare Neuroimmune Disorders Symposium (RNDS), Tricia Plumb, RN, MSN, of the University of Texas Southwestern, a research nurse and coordinator, spoke about how to get involved in research [00:00:30]. She explained the difference between interventional and observational trials and the ethics review and oversight that come before a study is offered [00:01:16]. Ms. Plumb covered informed consent, including that taking part is voluntary and that people can ask about risks, benefits, and other options [00:04:59]. She described where to find studies, including asking your care team, patient advocacy groups, listservs, ClinicalTrials.gov, and the clinical trial search in a patient portal such as MyChart [00:06:30]. She closed with audience questions about observational studies, a biorepository, and how placebo and blinded trials work [00:13:15].
Tricia Plumb, RN, MSN, earned her BS and Masters degree in Nursing from the University of Oklahoma. She coordinates educational and research opportunities for Dr. Greenbergs studies of rare neuroimmune disorders at University of Texas Southwestern/Childrens Health Dallas.
00:00 Welcome and Introduction
00:52 A Research Nurses Role
01:16 Interventional and Observational Trials
02:12 Ethics Review and Study Teams
04:59 Informed Consent Basics
06:30 Where to Look for Studies
08:32 Using ClinicalTrials.gov
10:23 Academic Centers and Networks
11:39 Finding Trials Through MyChart
13:15 Questions About Observational Studies
16:22 Placebo and Blinded Trials
19:47 Closing Thanks 2026 RNDS | How to Get Involved in Research](https://i.ytimg.com/vi/X7znkCF9jVg/mqdefault.jpg)
![2026 RNDS | Pediatric Symptom Toolkit: Fatigue, Pain, Mobility, and Bladder/Bowel Routines
In this session from the 2026 Rare Neuroimmune Disorders Symposium (RNDS), Sarah Hopkins, MD, MSPH, of Childrens Hospital of Philadelphia spoke about fatigue, pain, mobility, and bladder and bowel routines in children living with rare neuroimmune disorders. Dr. Hopkins described how fatigue differs from sleepiness and weakness, why it helps to bring it up early in a visit, and practical steps such as graded exercise, school schedule changes, sleep habits, and the five Ps of prioritizing, planning, pacing, positioning, and using assistance [00:00:58]. She reviewed neuropathic and neuromuscular pain, including medicines used off-label in children, cognitive behavioral therapy, physical and occupational therapy, TENS units, bracing, and spasticity options [00:07:26]. She then covered mobility at home and school, IEP and 504 plans, regular equipment sizing checks, service animals, driver rehabilitation, adaptive gaming, and adaptive sports [00:12:57]. She closed with timed bathroom plans for school, hydration, bowel regimens, and pelvic floor therapy [00:18:48].
Sarah Hopkins, MD, MSPH, graduated from the University of Arkansas College of Medicine in 2004 and completed her residency in pediatrics and neurology at Cincinnati Childrens Hospital Medical Center in 2009, where she remained on faculty for several years. Dr. Hopkins came to the Childrens Hospital of Philadelphia in 2014 and became Section Head of MS and Neuroinflammatory Disorders in 2017. She has an interest in inflammatory disorders of the spinal cord and directs the multi-disciplinary Myelitis Clinic at CHOP. She also has an interest in acute flaccid myelitis (AFM) and serves as a neurology consultant for the US Centers for Disease Control and Prevention for activities related to AFM surveillance. She is the site PI for the NIH AFM Natural History Study and the International Pediatric Opsoclonus Myoclonus Ataxia Syndrome Registry, and serves as Co-Director of the CHOP/Penn Age Span MS and Neuroinflammatory Disorders Fellowship.
00:00 Introduction and Plan for the Session
00:58 What Is Fatigue in Children
01:54 Causes of Fatigue and Raising It Early
03:49 Managing Physical and Cognitive Fatigue
05:33 The Five Ps and Fatigue Medicines
07:26 Pain in Children
09:19 Treating Neuropathic Pain
12:01 Spasticity and Neuromuscular Pain
12:57 Mobility at Home and School
16:23 Driving, Gaming, and Adaptive Sports
18:48 Bladder and Bowel Routines
20:39 Closing Thoughts 2026 RNDS | Pediatric Symptom Toolkit: Fatigue, Pain, Mobility, and Bladder/Bowel Routines](https://i.ytimg.com/vi/X9tMeikUb0A/mqdefault.jpg)
![2024 NMOSD Together | Community Q&A
During the 2024 NMOSD Together online event, Krissy Dilger of SRNA was joined by Dr. Elias Sotirchos of Johns Hopkins Hospital in Baltimore, Maryland. Dr. Sotirchos answered the audience’s questions about neuromyelitis optica spectrum disorder (NMOSD), exploring common symptoms like optic neuritis and myelitis, and rarer symptoms like area postrema syndrome, while distinguishing NMOSD from other diseases such as MOG antibody disease and multiple sclerosis [00:02:00].
The discussion also addressed the ongoing revisions in diagnostic criteria and the complexity faced by patients and neurologists due to overlapping symptoms and antibody statuses [00:10:45]. Additionally, it highlighted FDA-approved treatments for NMOSD, mentioning accessible therapies for people who are aquaporin-4 antibody positive and the challenges faced by people who are seronegative [00:22:15]. The talk concluded by examining the future prospects for NMOSD, focusing on the potential for immune education and myelin repair therapies [00:34:10]. Please note that the information shared during this session is for informational purposes only and is not medical advice.
Elias Sotirchos, MD is a neurologist at Johns Hopkins Hospital in Baltimore, Maryland. He specializes in the diagnosis, management, and treatment of neuroimmunological disorders that involve the central nervous system, including multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG)-associated disorder (MOGAD). His research focuses on developing and validating novel imaging and blood-based biomarkers of these conditions, and clinical trials of experimental therapeutic agents.
00:00 Introduction to NMOSD Diagnosis
01:23 Common Presentations of NMOSD
02:42 Distinguishing NMOSD from MOG Antibody Disease
04:55 FDA-Approved Treatments for NMOSD
07:29 Challenges with Seronegative NMOSD
10:03 Antibody Development and Immune Deficiency
16:37 Impact of Infections on NMOSD
21:37 Global Access to NMOSD Treatments
24:22 Diagnosing Sarcoidosis and NMOSD
26:46 Unusual Symptoms and Prodromal Phase in NMOSD
37:46 Choosing the Right Treatment for NMOSD
44:35 Future Directions: Cure and Repair for NMOSD
48:58 Conclusion and Final Thoughts 2024 NMOSD Together | Community Q&A](https://i.ytimg.com/vi/XU1gGGHEnCY/mqdefault.jpg)